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ABSTRACT
Objectives: Cancer is the second most common cause of death, with breast cancer (BC) as the most frequently diagnosed 
neoplasm among females. The origin of BC is multifactorial and depends on environmental and genetic factors. The dis-
ease presents a significant challenge due to its drug resistance and frequent metastasis. Thus, new effective therapies and 
metastasis prevention are much needed. Rosmarinic acid (RA) is a natural polyphenol which possesses the ability to inhibit 
BC cell proliferation and demonstrates cytotoxic properties against those cells. In our study, we examined the effect of RA 
on the expression of ZEB1, MDM2, ABCB1, PTEN and TWIST1 genes in MCF-7 breast cancer cells. 
Material and methods: MCF-7 cell cultures were treated with 0.2 µM doxorubicin (DOX) and 1.5, 15 or 50 µM of RA. Real-time 
PCR reaction was performed to analyze gene expression levels. 
Results: PCR analysis showed a significant increase of the ZEB1 gene expression, which was about 3-fold for DOX 0.2 µM, 
9-fold for 0.2 µM DOX + 1.5 µM RA and 0.2 µM DOX + 15 µM RA (p < 0.05), and about 6.5-fold for 0.2 µM DOX + 50 µM RA 
(p < 0.05). Furthermore, a decrease of the MDM2 gene expression was observed in all of the examined variants and was 
about 40–75% (p < 0.05). No influence of DOX and RA combined with DOX on the ABCB1, TWIST1 and PTEN genes was found. 
Conclusions: The results of our study suggest that RA might be used as an adjuvant therapeutic factor in BC treatment. 
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INTRODUCTION
Breast cancer (BC) is the second most common neoplasm 
worldwide, and the first among females [1]. It is also the sec-
ond most common cause of death among women [2]. Over 
1.7 million cases of breast cancer are diagnosed annually [3]. 
Numerous clinical and epidemiological studies have been con-
ducted to better understand the etiology and molecular basis 
of the disease but the search for effective cancer therapies 
continues. However, not only strategies of cancer treatment 
but also ways to prevent the development of the disease are 
of interest to the researchers. A variety of environmental and 
lifestyle risk factors affecting the development of breast cancer 
have already been known and they include the following: 
ionizing radiation, hormonal therapy, alcohol, diet, obesity 
and lack or low physical activity [1]. Some dietary ingredients 
like trans-fatty acids for example may increase the risk of de-
veloping chronic diseases, including cardiovascular diseases 
and cancer [4]. On the other hand, the literature offers many 
reports about food products, e.g. certain types of fruit, vegeta-
bles, grains or herbs, which are negatively correlated with can-
cer risk, breast cancer being no exception [4–6]. Polyphenols 
are one of the investigated food compounds which may play 
an important role in the prevention of BC [7]. They have been 
reported to take part in the process of interrupting or reversing 
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cellular signaling (e.g. NF-κB and AP1 pathways) by affecting 
intracellular signaling network molecules, which are involved 
in cell initiation and promotion. Polyphenols are also able to 
stop or reverse the progression of the disease. Importantly, the 
effect of their action is probably dose-dependent [8].
Rosmarinic acid (RA) is an ester of caffeic and 3,4-dihy-
droxyphenyllacitic acid, which commonly occurs in the leaves 
of Rosmarinus officinalis, from which it can be easily isolated, 
but it can also be found in other plants of the Lamiaceae 
and Boraginaceace families [9, 10]. This natural polyphenol 
is reported to possess anti-inflammatory, anti-mutagen, an-
ti-bacterial and anti-viral properties. Moreover, RA is an anti-
oxidant, which may help protect tissues from damage caused 
by reactive oxygen species (ROS) [11]. The results of various 
studies showed that RA has the ability to inhibit the prolifera-
tion of breast cancer cells (MDA-MB-231BO cells), what sug-
gests that this compound can inhibit bone metastasis from 
breast cancer [10]. The pathway of the NF-κB ligand receptor 
activator, (RANKL)/RANK/osteoprotegerin and suppression of 
IL-8 expression are suggested to take part in this process [12]. 
Moreover, RA shows cytotoxic properties against MCF-7 cells 
[13, 14]. Furthermore, the combination of RA and TNF-α is 
reported to induce apoptosis through inhibition of NF-κB 
activation in human dermal fibroblasts [15, 16]. RA also inhibits 
DNA methyltransferase activity, which is responsible for DNA 
methylation and silencing of many tumor suppressor genes 
[13]. However, the number of studies about the influence of 
RA on BC cells remains limited. The aim of this study was to 
examine the activity of RA against tumor cells by evaluat-
ing the expression level of the following genes: zinc finger 
E-box binding homeobox 1 (ZEB1), twist homolog 1 (TWIST1), 
MDM2 p53 binding protein homolog (MDM2), ATP-binding 
cassette, sub-family B (ABCB1), phosphatase and tensin ho-
molog (PTEN) involved in cell apoptosis and proliferation.
MATERIAL AND METHODS
Material
Rosmarinic acid (RA) and doxorubicin (DOX) were pro-
vided by Sigma-Aldrich. The MCF-7 cell line containing 
ER-positive human breast cancer cells was treated in the 
presence and absence of RA and DOX. MCF-7 cells as control 
line were cultured without DOX and RA. 
Cell culture
MCF-7 cells were cultured in Dulbecco’s modified ea-
gle’s medium (DMEM) (Sigma-Andrich). The medium was 
enriched with 10% fetal bovine serum (FBS) (Sigma-Aldrich) 
and 0.1% penicillin (100 U/mL)/streptomycin (100 µg/mL) 
(Sigma-Aldrich). The cells were cultured in an incubator at 
37°C with 5% CO2 atmosphere.
0.2 µM DOX was added to MCF-7/DOX cells. Four types 
of cell cultures (MCF-7, MCF-7/DOX, MCF-7/RA and MCF-
7/DOX/RA) were seeded at a density of 4 x 100 cells/mL and 
cultured for 160 h. After reaching the cell confluence, the me-
dium was removed and the cells were washed with phosphate 
buffered saline (PBS). Next, the cells were incubated in culture 
medium without FBS in the presence of RA (1.5 µM, 15 µM, 
50 µM), respectively for 24h, 48h, 72h and 96h. Cell growth was 
analyzed by counting viable cells in the presence of trypan blue 
(Sigma Aldrich) with a Bucker hemocytometer. To determine 
the antiproliferative activity for DOX and RA, we carried out the 
MTT assay adding 10 µL of MTT [3-(4, 5-dimethylthiazol-2-yl) 
-2, 5-diphenyltetrazolium bromide] solution obtained from 
SIGMA-Aldrich and then incubating for 4 h. The viable cells 
were visualized by the development of purple color due to 
formation of formazan crystals which were dissolved with 
100 µL of isopropyl alcohol at 0.05 N HCl. Next, the absorbance 
was measured at 570 nm on a microplate reader (Infinite 200, 
TECAN) using the wavelength of 655 nm as reference. 
RNA extraction and cDNA synthesis
The isolation of total cellular RNA was performed accord-
ing to the manufacturer’s protocol of TriPure Isolation Reagent 
(Roche). The RNA pellet was washed with 70% ethanol and dis-
solved in DEPC water. Next, the analysis of RNA concentration 
and purity was performed using the absorbance measurement 
at 260 nm and 280 nm in a spectrophotometer (NanoDrop, 
Thermo Fisher Scientific. The samples were stored in -80°C.
2 µg of total RNA were used to synthesize complemen-
tary DNA. The reaction was performed using Transcriptor 
First-Strand Synthesis System (Roche) and oligo(dT)20 prim-
er according to the manufacturer’s protocol. The obtained 
transcripts were used directly for the real-time PCR (RT-PCR) 
or stored at -20°C.
Real-time PCR
The expression level of the studied genes (ZEB1, ABCB1, 
MDM2, TWIST1, PTEN) was analyzed by real-time quantitative 
PCR using RealTime ready Custom Panel 96 kit (Roche). The 
reaction was conducted using a LightCycler® 96 Instrument 
(Roche, Germany) and a LightCycler®480 Probes Master kit 
(Roche, Germany). As a housekeeping gene for normaliza-
tion, the ACTB gene was applied. The activation of PCR 
reaction was initiated at 95°C for 5 min. The denaturation 
step was carried at 95°C, an annealing step at a 61°C and 
an extension step at 72°C. The increase in fluorescence of 
PCR products was monitored and measured and the data 
were analyzed with the LightCycler® 96 software.
Statistical analysis
The results were expressed as mean ±SEM. ANOVA was 
used to determine the statistical significance of the differ-
ences between the control and experimental group. The 
threshold of significance was p < 0.05.
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Next, we examined the effect of RA on the growth and 
viability of MCF-7 cells. Using a Bucker hemocytometer, 
we counted viable cells in the presence of trypan blue. We 
observed a significant inhibition of cell growth after 4 days 
of treatment both, for the mixture of DOX with RA and only 
DOX (Fig. 2). Interestingly, cell growth inhibition was similar, 
independently of the RA dose. 
Moreover, we applied the MTT assay to evaluate the 
cytotoxic effect of RA. As is shown in Figure 3, treatment of 
the MCF-7 cells with 1.5 µM, 15 µM and 50 µM concentra-
tions of RA with combination of 0.2 µM DOX resulted in 
a significant (p < 0.05) increase in cell death after 4 days. RA 
without DOX had no significant effect. 
DISCUSSION
RA shows certain biological and pharmacological ac-
tivities which can be used for breast cancer prevention and 
therapy. In this work, the effects RA on the expression level 
of selected genes (ZEB1, ABCB1, MDM2, TWIST1 and PTEN) 
in MCF-7 breast cancer cells were analyzed. 
In our study, we demonstrated that both, MCF-7/DOX 
and MCF-7/DOX/RA cells are characterized by significantly 
increased expression of the ZEB1 gene, with about 2- and 
3-fold for breast cancer cells treated with 50 µM RA with DOX 
and 1.5/15 µM RA with DOX, respectively as compared to 
cells treated only with DOX. This gene is responsible for cod-
ing a zinc finger E-box-binding homeobox1 protein, which 
binds to specific DNA sequences (E-boxes) and controls the 
expression of the targeted genes [17]. An aberrant expres-
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Figure 3. The effect of rosmarinic acid (RA) with doxorubicin (DOX) 
on the growth of breast cancer cell line. MCF-7 cells were treated with 
different concentrations of RA for 24, 48, 72 and 96h, and the viability 
was assessed by MTT assay. Results are expressed as percentage 
of corresponding control value and represent the mean ± SD of 3 
repeats 
Figure 1. The influence of rosmarinic acid (RA) and doxorubicin (DOX) 
on gene expression in MCF7 cells after 96h. The control group was 
defined as 100%. Data were presented as mean ± SEM. *p < 0.05 as 
compared with the control group
Figure 2. Percentage of MCF7 cell survival after treatment with 
different concentrations of rosmarinic acid (RA) (1.5, 15 and 50 µM), 
incubated for 4 days in the presence of DOX (0.2 μM). Control group 
without RA and DOX
RESULTS
In this study, we examined the influence of rosmarinic 
acid on the expression of selected genes in MCF-7 breast 
cancer cells, which were treated with 1.5 µM, 15 µM and 
50 µM of RA in 96h (Fig. 1). Real-time PCR reaction was per-
formed to define gene expression level. The increased level 
of the ZEB1 gene expression was observed for MCF-7/DOX 
and MCF-7/DOX/RA cells (about 3-fold for 0.2 µM DOX, 
9-fold for 0.2 µM DOX + 1.5 µM and 0.2 µM DOX + 15 µM 
RA and about 6.5-fold for 0.2 µM DOX + 50 µM, p < 0.05). 
We also noticed a decreased mRNA level of the MDM2 gene 
in MCF-7 cells when treated with 0.2 µM DOX + 1.5 µM RA, 
0.2 µM DOX + 15 µM RA and 0.2 µM DOX + 50 µM RA. No 
significant influence of RA on the mRNA level was found 
for the ABCB1, TWIST1 and PTEN genes as compared to the 
control MCF-7 cells. 
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sion of ZEB1 has been observed in many cancer types and 
is considered to be associated with poor prognosis in some 
cancers (breast, ovarian, lung and pancreatic) [18–21]. The 
protein encoded by ZEB1 has been identified as the key fac-
tor in BC differentiation and metastasis regulation. Patients 
with various tumors, including breast cancer, demonstrating 
high ZEB1 expression responded poorly to chemotherapy 
[21]. In another study, a positive correlation between hu-
man telomerase reverse transcriptase (hTERT) and ZEB1 ex-
pression in breast cancer was discovered, which indicates 
that this gene controls cancer cell proliferation and apop-
tosis [17]. Therefore, the ZEB1 gene expression is a negative 
marker in breast cancer treatment, survival and metastasis. 
We observed a decrease of the MDM2 gene expression 
in cells treated with RA in different concentrations. The 
MDM2 gene encodes a ring finger domain-containing pro-
tein MDM2, which belongs to mouse double minute (MDM) 
family [22]. This protein is a negative regulator of p53 tumor 
suppressor which binds and ubiquitinates p53, resulting 
in its easier proteasomal degradation [23]. The increased 
level of p53 protein is able to induce transcription of MDM2, 
which leads to degradation of p53 and generates a negative 
feedback loop [24]. This process has been observed in various 
types of cancer, e.g. overexpression of MDM2 occurs in some 
types of breast cancer [22]. MDM2 has been also reported to 
negatively affect some other tumor suppressors, like SIRT6 or 
ERβ [22]. Therefore, inhibitors of the MDM2 pathway have 
attracted much attention of various researchers. A number of 
small-molecule drugs which inhibit the MDM2 activity have 
already been discovered [23]. Carnosol, which is a natural 
phenolic diterpene occurring in rosemary, has been discov-
ered to possess the ability to inhibit MDM2/p53 complex, 
thus exhibiting anti-cancer properties [25]. In our study, 
we observed a decreased MDM2 expression in cancer cells 
treated with RA, which is also a polyphenol present in rose-
mary, suggesting an anti-cancer effect of RA on breast cancer.
We analyzed the influence of RA on other genes, like 
ABCB1, TWIST1 and PTEN. The ABCB1 gene encodes a P-gly-
coprotein (P-gp), which is an ATP-dependent efflux pump 
located in cell membrane. This gene is also associated with 
multidrug resistance (MDR) and responsible for ATP-de-
pendent efflux of anticancer drugs [26, 27]. Overcoming 
multidrug resistance to chemotherapeutics is an important 
aspect of cancer treatment and recovery. The RA also does 
not influence the TWIST1 gene expression. The transcription 
factor TWIST, encoded by TWIST1 gene, is an oncoprotein 
inducing cell migration and invasion in cancer cells, includ-
ing breast cancer cells, while depletion of TWIST1 inhibits 
metastasis [28]. Overexpression of TWIST1, often found in 
various tumors, induces epithelial-mesenchymal transition 
(EMT), a process involved in cancer metastasis [29]. However, 
it is an unstable protein and its expression can be upregu-
lated, for example by the activation of β-TRCP (β-transducin 
repeat-containing protein) and/or IKKβ (Kappaβ kinase β) 
[30]. Garcinol, a natural polyphenol, is reported to sensi-
tize breast cancer cells to taxol therapy, which is achieved 
through the suppression of NF-κB/Twist1 signaling pathway 
[31]. Our investigation of the possible effect of RA combined 
with a chemotherapeutic, DOX, on BC cells showed a lack 
of influence of RA on the TWIST1 expression. Moreover, the 
PTEN gene expression was examined in breast cancer cells 
treated with RA. Another phenolic compound, isoliquiriti-
genin, is reported to have the ability to increase PTEN expres-
sion and, as a result, inhibit aberrant Akt signaling [32]. PTEN 
is a significant negative regulator of the PI3K/Akt/mTOR 
pathway, which is involved in many cellular actions like pro-
liferation, migration and differentiation. Also, this pathway 
is involved in cancer cell survival, proliferation and progres-
sion [33]. However, RA did not affect the expression level of 
PTEN in our study. 
CONCLUSIONS
The results of our study may contribute to better under-
standing of the mechanism of RA effect on cancer. Further 
studies are necessary to provide evidence for the safety, 
effectiveness and clinical use of RA in cancer treatment. 
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